Erratum: Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing (Familial Cancer (2006) DOI 10.1007/s10689-006-0002-z);Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing

Familial Cancer

Volumn 5, Issue 4, 2006, Pages 327-335

  Kram, Vardit ^a   Peretz, Tamar ^a   Sagi, Michal ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Attitudes; BRCA; Preventive mastectomy; Preventive oophorectomy

Indexed keywords

ADULT; ARTICLE; BODY IMAGE; CONTROLLED STUDY; CULTURAL FACTOR; FEMALE; GENE MUTATION; GENETIC COUNSELING; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MASTECTOMY; ONCOGENE; OVARIECTOMY; PATIENT ATTITUDE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE;

EID: 33845543468     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-006-0013-9     Document Type: Erratum

References (43)

1. Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408
2. The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310-1316
3. Risch HA, McLaughlin JR, Cole DE et al (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700-710
4. King MC, Marks JH, Mandell JB (2003) New York Breast Cancer Study Group. Breast cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643-646
5. Hartmann LC, Sellers TA, Schaid DJ, et al (1999) Clinical options for women at high risk for breast cancer. Surg Clin North Am 79:1189-1206
6. Burke W, Daly M, Garber J et al (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2. JAMA 277:997-1003
7. Seidman AD. BRCA1/2 mutations: implications for prognosis, treatment, outcome, prevention. American Society of Clinical Oncology 35th Annual Meeting. 1999
8. Hartmann LC, Schaid DJ, Woods JE et al (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77-84
9. Hartmann LC, Sellers TA, Schaid DJ et al (2001) Efficacy of prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93:1633-1637
10. Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 346:1616-1622
11. Kauff ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615
12. Schrag D, Kuntz KM, Garber JE et al (1997) Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336: 1465-1471
13. Grann VR, Panageas KS, Whang W et al (1998) Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1 positive or BRCA2 positive patients. J Clin Oncol 16:979-985
14. Wagner TM, Moslinger R, Langbauer G et al (2000) Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group. Br J Cancer 82:1249-1253
15. Frost MH, Schaid DJ, Sellers TA et al (2000) Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 284:319-324
16. Hopwood P, Lee A, Shenton A et al (2000) Clinical followup after bilateral risk reducing ('prophylactic') mastectomy: mental health and body image outcomes. Psycho-Oncology 9:462-472
17. Lerman C, Hughes C, Croyle RT et al (2000) Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 31:75-80
18. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT et al (2000) Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 355:2015-2020
19. Unic I, Verhoef LC, Stalmeier PF et al (2000) Prophylactic mastectomy or screening in women suspected to have the BRCA1/BRCA2 mutation: a prospective pilot study of women's treatment choices and medical decision-analytic recommendations. Med Decis Making 20:251-262
20. Di Prospero LS, Seminsky M, Honeyford J et al (2001) Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey. CMAJ 164:1005-1009
21. Cappelli M, Surh L, Humphreys L et al (2001) Measuring women's preferences for breast cancer treatments and BRCA1/BRCA2 testing. Qual Life Res 10:595-607
22. Julian-Reynier CM, Bouchard LJ, Evans DG et al (2001) Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer 92:959-968
23. Weitzel JN, McCaffrey SM, Nedelcu R et al (2003) Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 138:1323-1328
24. Botkin JR, Smith KR, Croyle RT et al (2003) Genetic testing for a BRCA1 mutation: Prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet 118A:201-209
25. Scheuer L, Kauff N, Robson R et al (2002) Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20:1260-1268
26. Schwartz MD, Kaufman E, Penkin B et al (2003) Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA1 mutation testing. J Clin Oncol 21:4034-4041
27. Lodder LN, Frets PG, Trijsburg RW et al (2002) One year follow up of women opting for presymptomatic testing for BRCA1 and BRCA1:emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat 73:97-112
28. Wainberg S, Husted J (2004) Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Cancer Epidemiol Biomarkers Prev 13:1989-1995
29. Struewing JP, Abeliovich D, Peretz T et al (1995) The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11:198-200
30. Oddoux C, Struewing JP, Clayton CM et al (1996) The carrier frequency of the BRCA2 617delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14:188-190
31. Roa BB, Boyd AA, Volcik K et al (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14:185-187
32. Abeliovich D, Kaduri L, Lerer I et al (1997) The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60:505-514
33. Beller U, Halle D, Catane R et al (1997) High frequency of BRCA1 and BRCA2 mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history. Gynecol Oncol 67:123-126
34. Bar-Sade RB, Theodor L, Gak E, et al (1997) Could the 185delAG BRCA1 mutation be an ancient Jewish mutation? Eur J Human Gent 5:413-416
35. Lerer I, Wang T, Peretz T et al (1998) The 8765delAG mutation in BRCA2 is common among Jews of Yemmenite extraction. Am J Hum Gent 63:272-274
36. Watson M, Foster C, Eeles R et al (2004) Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort. Br J Cancer 91:1787-1794
37. Lynch HT, Organ CH Jr, Harris RE et al (1978) Familial cancer: implications for surgical management of high-risk patients. Review. Surgery 83:104-113
38. Nguyen HN, Averette HE, Janicek M. (1994) Ovarian carcinoma. A review of the significance of familial risk factors and the role of prophylactic oophorectomy in cancer prevention Review. Cancer 74:545-555
39. Julian-Reynier CM, Eisinger F, Moatti JP et al (2000) Physicians' attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines. Eur J Hum Genet 8:204-208
40. Geller G, Bernhardt BA, Doksum T et al (1998) Decisionmaking about breast cancer susceptibility testing: how similar are the attitudes of physicians, nurse practitioners, and at-risk women?. J Clin Oncol 16:2868-2876
41. Matloff ET, Shappel H, Brielly K et al (2000) What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery and insurance discrimination. J Clin Oncol 18:2484-2492
42. Armstrong K, Stopper J, Calzone K et al (2002) What does my doctor think? Preferences for knowing the doctor's opinion among women considering clinical testing for BRCA1/2 mutations. Genetic testing 6:115-118
43. Metcalfe KA, Liede A, Hoodfar E et al (2000) An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counseling. J Med Genet 37:866-874